Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Earth Science Tech's Debt-to-EBITDA or its related term are showing as below:
ETST'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.25 Med: -0.04 Max: 0.24
Current: 0.03
During the past 13 years, the highest Debt-to-EBITDA Ratio of Earth Science Tech was 0.24. The lowest was -3.25. And the median was -0.04.
ETST's Debt-to-EBITDA is ranked better than 94.78% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs ETST: 0.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Earth Science Tech Debt-to-EBITDA Related Terms
Earth Science Tech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Earth Science Tech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ETST vs IXHL, BTAI, TLPH: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Earth Science Tech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Earth Science Tech Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Earth Science Tech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Earth Science Tech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Earth Science Tech (ETST) has a Debt-to-EBITDA of 0.04 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Earth Science Tech. According to the industry distribution chart, Earth Science Tech ranks #36 out of 689 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Earth Science Tech's Debt-to-EBITDA too high?
Earth Science Tech's current Debt-to-EBITDA is 0.04. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Earth Science Tech's value of 0.04 is 97.6% below this industry median. Based on the distribution chart, Earth Science Tech ranks #36 out of 689 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Earth Science Tech has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Earth Science Tech's Debt-to-EBITDA compare to IXHL and BTAI?
According to the Drug Manufacturers industry distribution chart, Earth Science Tech ranks #36 out of 689 companies for Debt-to-EBITDA. This places Earth Science Tech in the top 5% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.68. Earth Science Tech's value of 0.04 is 97.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Earth Science Tech's current Debt-to-EBITDA of 0.04 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Earth Science Tech. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Earth Science Tech's current Debt-to-EBITDA is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Earth Science Tech stock overvalued right now?
Based on GuruFocus' analysis, Earth Science Tech (ETST) is currently considered Possible Value Trap. The stock's GF Value™ is $0.24, compared to a current price of $0.14 — trading 41.7% below its estimated fair value. The current Debt-to-EBITDA is 0.04 and 97.6% below the Drug Manufacturers industry median of 1.68. Earth Science Tech's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Earth Science Tech (ETST), the current Debt-to-EBITDA is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Earth Science Tech (ETST) Overvalued in 2026?
Based on GuruFocus' analysis, Earth Science Tech stock appears to be undervalued.
The current stock price of $0.14 is trading 41.7% below its estimated GF Value™ of $0.24.
GuruFocus considers Earth Science Tech to be Possible Value Trap.
Key valuation signals for ETST:
Debt-to-EBITDA: 0.04
GF Value™: $0.24 vs. price of $0.14 (41.7% below fair value)
Industry Position: 97.6% below the Drug Manufacturers median (#36 of 689)
No single metric tells the full story. See the ETST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Earth Science Tech Inc is a diversified holding company. The company focuses on the health and wellness sector. The Company's principal operating plan is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business. The core of the Company's value proposition is the seamless integration of patient care, from consultation to fulfillment.
37GF Score
Get the complete analysis for ETST
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETST has been successfully added to your 
